From Barclays: >We expect significant focus on secondary endpoints of overall survival (OS) and cancer related symptoms and believe that clinician rated progression is likely more indicative of overall patient benefit on these metrics than that from centralized radiologists.<
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.